Bypass of cell cycle arrest induced by transient DNMT1 post-transcriptional silencing triggers aneuploidy in human cells
© Barra et al; licensee BioMed Central Ltd. 2012
Received: 22 September 2011
Accepted: 3 February 2012
Published: 3 February 2012
Aneuploidy has been acknowledged as a major source of genomic instability in cancer, and it is often considered the result of chromosome segregation errors including those caused by defects in genes controlling the mitotic spindle assembly, centrosome duplication and cell-cycle checkpoints. Aneuploidy and chromosomal instability has been also correlated with epigenetic alteration, however the molecular basis of this correlation is poorly understood.
To address the functional connection existing between epigenetic changes and aneuploidy, we used RNA-interference to silence the DNMT1 gene, encoding for a highly conserved member of the DNA methyl-transferases. DNMT1 depletion slowed down proliferation of near-diploid human tumor cells (HCT116) and triggered G1 arrest in primary human fibroblasts (IMR90), by inducing p53 stabilization and, in turn, p21waf1 transactivation. Remarkably, p53 increase was not caused by DNA damage and was not observed after p14-ARF post-transcriptional silencing. Interestingly, DNMT1 silenced cells with p53 or p14-ARF depleted did not arrest in G1 but, instead, underwent DNA hypomethylation and became aneuploid.
Our results suggest that DNMT1 depletion triggers a p14ARF/p53 dependent cell cycle arrest to counteract the aneuploidy induced by changes in DNA methylation.
KeywordsG1 arrest aneuploidy DNA methylation DNMT1
Genomic instability is a characteristic of the majority of human tumors and is considered a driving force for tumorigenesis. Various forms of genome instability have been described and characterized by an increased rate of a number of different genetic alterations [1, 2]. Most cancers show a form that is called chromosomal instability (CIN), which refers to the high rate of numerical and structural chromosome changes found in cancer cells compared to normal cells. Numerical CIN is characterized by gains and losses of whole chromosomes (aneuploidy) during cell proliferation. Mutations in genes encoding mitotic regulators  and in genes controlling centrosome numbers and tumor suppressors [4–7] have been suggested as molecular defects underlying aneuploidy.
Nevertheless, correct chromosome structure and function may play a role in the stabilization and normal functioning of chromosome segregation. Indeed, it is now accepted that gene expression and chromosome organization are mainly affected by epigenetic marks and may be implicated in the normal chromosome segregation process. Thus, epigenetic alterations should be considered as a cause of aneuploid cells generation . In fact, imbalance in cytosine methylation of CpG islands is a recurrent event in human sporadic cancers. Hypomethylation and hypermethylation occur at specific but different sites within the cancer cell genome and can precede malignancy. Global genome hypomethylation in breast, ovarian, cervical and brain tumors increases with increasing malignancy . However, it is still object of investigation the mechanism(s) that correlates hypomethylation with tumor initiation-progression. Several hypotheses have been proposed, including chromosomal instability induced by hypomethylation of pericentromeric regions .
DNA-methyltransferases (DNMTs) - namely DNMT1, DNMT3a and DNMT3b in humans - are directly involved in DNA methylation. DNMT1 differs from the other two human DNA methylases, DNMT3a and DNMT3b, mainly because it is unable to methylate DNA with both strands unmethylated (de novo methylation) . DNMT1 is able to restore DNA methylation patterns during S-phase of the cell cycle and it has been recently implicated in genomic stability . In addition, DNMT1 was found deregulated in different human tumors suggesting its involvement in tumor initiation/progression. To investigate DNMT1 implication in the generation of chromosomal instability (aneuploidy), we evaluated the effects of its depletion by RNA interference in primary human fibroblasts (IMR90) and in near diploid human tumor cells (HCT116). DNMT1 post-transcriptional silencing in IMR90 cells resulted in G1 arrest, associated with increased expression of p21WAF1-Cip1 and p53 stabilization. p53 stabilization was not caused by DNA damage. Simultaneous p14ARF and DNMT1 transcriptional silencing in IMR90 cells did not result in p53 stabilization and G1 arrest. Accordingly, HCT116 cells, that are p14ARF-null  did not arrest in response to DNMT1-depletion. Thus, overriding the G1 arrest after DNMT1-depletion resulted in global DNA hypomethylation and aneuploidy.
Our results suggest that DNMT1 deficiency induces different outcomes depending on the genetic background of the cells. In IMR90 cells DNMT1 depletion resulted primarily in cell cycle arrest, while in HCT116 tumor cells, missing p14ARF, induced aneuploidy, probably affecting the correct chromosomal segregation by altering the DNA methylation pattern.
DNMT1 depletion induces growth delay in HCT116 cells and G1 arrest in IMR90 cells
It is conceivable that DNMT1 depletion, causing defects in DNA methylation, will be sensed as a stress signal eliciting a cell cycle response (arrest/delay) in the cell. To address this further, we did cytofluorimetric analyses of IMR90-siDNMT1 and HCT-siDNMT1 cells at 72 hours post-transfection to compare them with control cells (siGFP transfected). To assess the number of cells actively replicating DNA (S-phase cells), cells were labeled with BromodeoxiUridine (BrdU) that is incorporated during DNA synthesis, and were then analyzed simultaneously for BrdU incorporation and propidium iodide (PI) staining. Cytofluorimetric analyses showed a large decrease in the number of IMR90-siDNMT1 S-phase cells (BrdU positive) and accumulation of the cells in the G1-phase (Figure 1E) indicative of a G1 arrest. On the contrary, HCT-siDNMT1 cells did not arrest in G1 but they accumulated in S-phase delaying the G2/M phase entry (Figure 1E). Collectively, these findings highlight a different response to DNMT1 depletion of IMR90 human fibroblasts versus HCT116 cells.
IMR90 cells sense DNMT1 decrease and activate a p53-controlled pathway
These results suggest that p53 might be involved in the G1 arrest observed in IMR90-siDNMT1 cells by transactivating p21WAF1-Cip1. To investigate this further, IMR90 cells were simultaneously transfected with siRNAs specifically targeting DNMT1 and p53. Real time RT-PCR and Western blot analyses confirmed reduced expression of DNMT1 and p53 in these silenced cells in comparison to control cells (Figure 2D, E). In addition, western blotting showed p21WAF1-Cip1 reduction in these double silenced cells (Figure 2E), indicating its correlation with p53 depletion.
At 72 hours post-transfection the number of double transfected cells was similar to that of control cells (Figure 2F top panel). By counting cells every 24 hours, we noticed that cells proliferate as the control cells (Figure 2F central panel). Cytofluorimetric analyses showed also that siDNMT1/p53 cells progressed normally in the cell cycle, while IMR90-siDNMT1 arrested in G1 (Figures 2F, 1E). These findings suggest that p53 reduction allowed an incorrect cell cycle progression of DNMT1-depleted cells.
P14ARF is involved in a cell response to DNMT1 depletion
DNMT1 depletion induces a global DNA demethylation
DNA methylation status after DNMT1 silencing in HCT116
% Methylated DNA
5,9% ± 0,4
1,95% ± 1,06
IMR90 and HCT116 cells become aneuploid if they do not arrest in G1 following DNMT1 depletion
To ascertain that lack of G1 arrest in presence of decreased DNMT1, as observed in HCT-siDNMT1 cells, contributed to aneuploidy we did a cytogenetic analysis of siDNMT1/p53 and siDNMT1/p14ARF IMR90 cells that despite DNMT1 depletion proliferated incorrectly. This experiment showed that the number of IMR90-siDNMT1/p53 mitotic cells (mitotic index 3%) was similar to that of control IMR90 cells and likely reflects the ability to bypass the G1 arrest. Most importantly the majority (70%) of the observed mitosis (n = 35) were hypodiploid (Figure 6B) as shown by HCT-siDNMT1 cells that did not arrest in G1 (Figure 6A). IMR90-siDNMT1/p14ARF showed the same mitotic index of control cells and were mainly hypodiploid (Figure 6B). These results show that in absence of the G1 arrest provoked by DNMT1 depletion the analyzed cells acquired aneuploidy. This last finding suggests that the G1 arrest is induced to protect cells from aneuploidy likely due to DNA hypomethylation that would occur after DNMT1 depletion.
DNA methylation, histone methylation and deacetylation combine to bring about DNA hypercondensation typical of centromeric and pericentromeric chromatin [27, 28]. DNMT1 downregulation might alter this combination leading to chromatin decondensation that could determine chromosomes missegregation. Imbalance in cytosine methylation (hypomethylation) and deregulation of DNA methyl-transferases, in particular DNMT1, are recurrent in human sporadic cancers and it seems that they could be involved in the acquisition of chromosomal instability . Deregulated expression of DNMT1 is frequently observed in human tumors [12, 29–31] however its correlation with cancer progression is still object of investigation.
By using two different cell types, primary human fibroblasts (IMR90) and stable near-diploid tumor cells (HCT116), we determined that DNMT1 transient depletion had different outcomes related to the genetic context of the cell. We observed that the transient DNMT1 post-transcriptional silencing promptly induced G1 arrest in human fibroblasts, but only a slight decrease of cell proliferation in HCT116 cells. As a consequence of the proliferation arrest mediated by DNMT1 transient depletion IMR90 fibroblasts showed very few mitotic cells. These findings suggest the existence in IMR90 fibroblasts of a p53 controlled cellular pathway that following DNMT1 depletion activates a putative G1-checkpoint that is not properly working in tumor HCT116 cells. The p53 involvement in response to DNMT1 depletion was further suggested by the finding that double silenced IMR90 cells (IMR90-siDMT1/p53) did not arrest anymore. Our observation that IMR90 cells restarted proliferation after 144 hours from siDNMT1 transfection, and that the p53 amount decreased, are additional evidence of the existence of a p53 controlled checkpoint, that is activated in response to DNMT1 depletion. The absence of γH2AX positive foci rules out that the DNMT1 depletion activates the classic p53 pathway induced by DNA damage. This is confirmed by the fact that HCT116 cells responded correctly to the presence of DNA damage by increasing p53 protein levels, but were unable to halt cellular proliferation in response to transient DNMT1 depletion. Altogether, these results suggest that in HCT116 cells is missing some factor necessary to activate the pathway induced by DNMT1-depletion.
The fact that IMR90-siDNMT1/p14ARF cells did not arrest in G1 indicates that p14ARF is necessary for the cell cycle arrest in IMR90 cells, and also suggests p14ARF as the specific intermediate necessary to activate/stabilize p53 in response to DNMT1 depletion. Thus, the presence of dysfunctional p14ARF in HCT116 cells  might explain why these cells cannot properly respond to DNMT1 depletion resulting then in unscheduled progression from G1 to S phase of the cell cycle.
DNMT1 silencing and lack of G1 arrest resulted in the induction of aneuploidy in both cell lines analyzed. Recently, it has been proposed that aneuploidy found in different human tumors is caused directly by hypomethylation of specific chromosomal regions that are usually hypermethylated, such as pericentromeric regions, whose function is correlated with chromosome structure (centromere formation) and faithful segregation [23–26]. The incorrect cell cycle progression of HCT116 cells was correlated with a reduction of DNA methylation degree and we hypothesize that DNA hypomethylation could be the cause of aneuploidy in these cells.
Finally, increase in the number of IMR90 aneuploidy cells was seen only after incorrect G1/S progression induced by p53 and p14ARF post-transcriptional silencing. This last finding again highlights the existence of a pathway p14ARF/p53 controlled able to preserve normal cells from incorrect DNA methylation status affected by DNMT1 lack.
Cells and cell culture
Human primary fibroblasts (IMR90 passage 12, ATCC) were cultured in EMEM supplemented with: 10% FBS (GIBCO, Life Technologies), 100 units/ml penicillin and 0,1 mg/ml streptomycin (GIBCO, Life Technologies), 1% NEAA (GIBCO, Life Technologies), the human colon cancer cell line HCT116  was cultured in DMEM supplemented with: 10% FBS, 100 units/ml penicillin and 0,1 mg/ml streptomycin. Cells were cultured in a humidified atmosphere of 4% CO2 in air at 37°C. For siRNAs transfection 1, 5 × 105 IMR90 cells and 2, 5 × 105 HCT116 cells were plated in 6-well dishes and incubated at 37°C. Specific siRNAs duplex were mixed with Lipofectamine2000 Reagent (Invitrogen, Life Technologies), according to manufacturer's recommendation and added to the cells. After 6 hours at 37°C, the transfection medium was replaced with fresh medium. To silence genes of interest post-transcriptionally, cells were transfected with siRNAs targeting DNMT1 (siDNMT1: 5'- AUU ACG UAA AGA AGA AUU A dTdT-3')  at final concentrations of 60, 80 and 100 nM, siRNAs targeting TP53 (si p53: 5'-GCA UGA ACC GGA GGC CCC AUtt-3')  and p14ARF (sip14: 5'-GAA GAU CAG GUC AUG AUG Att-3')  at a final concentration of 60 nM. All siRNAs were synthesized by Eurofins-MWG.
Real time RT-PCR
Primers to be used in Real time RT-PCR experiments were designed with Primer Express software (Applied Biosystems, Life Technologies) choosing amplicons of approximately 70-100 bp. The selected sequences were tested against public databases (BLAST) to confirm the identity of the genes. Total RNA was extracted from cells by using the RNAeasy mini kit (GE) or the "All prep DNA/RNA kit" (Qiagen) according to the manufacture's instruction. RNA was reverse-transcribed in a final volume of 100 μL using the High Capacity c-DNA Archive kit (Applied Biosystems, Life Technologies) for 10 minutes at 25°C and 2 hours at 37°C. For each sample 2 μL of cDNA, corresponding to approximately 100 nag of reverse transcribed RNA, was analyzed by Real time RT-PCR (95°C for 15 sec, 60°C for 60 sec repeated for 40 cycles), in quadruplicate, using the ABI PRISM 7300 instrument (Applied Biosystems). Real time RT-PCR was done in a final volume of 20 μl comprising 1x Master Mix SYBR Green (Applied Biosystems, Life Technologies) and 0, 3 μM of forward and reverse primers for: DNMT1 (Fw: 5'-GCACCTCATTTGCCGAATACA-3'; Rev: 5'-TCTCCTGCATCAGCCCAAATA-3'), TP53 (Fw: 5'-TTCGACATAGTGTGGTGGTGC-3'; Rev: 5'- AGTCAGAGCCAACCTCAGGC-3'), p21WAF1-Cip1 (Fw: 5'-CTGGAGACTCTCAGGGTCGA-3', Rev: 5'-CGGATTAGGGCTTCCTCTTG-3'), p14ARF (Fw: 5'- TGATGCTACTGAGGAGCCAGC-3', Rev: 5'-AGGGCCTTTCCTACCTGGCTC-3'), GAPDH (Fw: 5'-CTCATGACCACAGTCCATGCC-3', Rev: 5'-GCCATCCACAGTCTTCTGGGT-3'). Data were analyzed by averaging quadruplicates Ct (cycle threshold). Levels of RNA expression were determined by using the SDS software version (Applied Biosystems, Life Technologies) according to the 2-ΔΔct method. Levels of RNA expression of selected genes were normalized to the internal control GAPDH.
Protein concentration was measured using the Bio-Rad Protein Assay (Bio-Rad Laboratories). Proteins (40 μg) were separated by 10% SDS-PAGE containing 0,1% SDS and transferred to Hybond-C nitrocellulose membranes (Amersham Life Science) by electro-blotting. The membranes were sequentially incubated with goat anti-DNMT1, rabbit anti-p21WAF1-Cip1, rabbit anti-pRb (Santa Cruz, CA), mouse anti-p53 (Abcam, UK) as primary antibodies, and HRP-conjugated mouse, rabbit (Abcam, UK) and goat (Santa Cruz, CA) Gig as secondary antibodies. The target protein was detected with enhanced chemiluminescence Western blotting detection reagents (Pierce, Thermo Scientific). We used also mouse anti-β-tubulin (SIGMA, Italy) as internal control of loading. Membranes were stained by Ponca-Red to confirm equivalent loading of total protein in all lanes.
Cell cycle analysis
Asynchronously growing cells were treated with 80 nM siDNMT1 alone or together with 60 nM sip53 for 72 hours and released into complete medium with BromodeoxiUridine (BrdU, SIGMA, Italy) 0, 2 μg/ml for one hour. DNA content was determined using Propidium Iodide (PI, SIGMA, Italy) staining by treating cells with PBS solution containing 4 μg/ml of PI and 40 μg/ml RNase. Analysis of BrdU labelled cells was conducted as described previously  and samples were analyzed on a FACSCanto (Becton Dickinson). Analysis of IMR90-siDNMT1/p14ARF cell cycle was made by PI staining of DNA content. Experiments were repeated at least twice, 10000 events were analyzed by FACSDiva software.
Cells were seeded onto glass cover slides 24 hours before the analysis. They were then, treated with 0,2 μg/ml colcemid (Demecolcine, SIGMA, Italy) for three (HCT116) four (IMR90) or eight (IMR90-siDNMT1) hours. Cell were swollen in 75 mM KCl at 37°C, fixed with methanol/acetic acid (3:1 v/v) The cover slides were then air-dried and stained with 3% GIEMSA in phosphate-buffered saline for 10 minutes. Chromosome metaphases were evaluated using a Zeiss Axioskop microscope under a 63× objective. The analysis was repeated three times for each cell types.
Phosphorylated H2A.X immunostaining: IMR90 and HCT116 were grown on glass coverslips after siRNAs transfection. Cells on coverslips were fixed with cold methanol (-20°C), permeabilized with 0.01% Triton × (Sigma, Italy) and blocked with 0.1% BSA, both at room temperature. Then, coverslips were incubated with phosphorylated H2A.X rabbit polyclonal antibody (1:100 in PBS-BSA 0.1%, Upstate) overnight at 4°C, washed in PBS and incubated with a FITC-conjugated rabbit anti-mouse (Sigma, Italy) diluted 1:100 in PBS-BSA 0,1%) for 1 hour at 37°C. Nuclei were visualized with 1 μg/ml of 4',6-Diamidino-2-phenylindole (DAPI) and examined on a Zeiss Axioskop microscope (Zeiss, Germany) equipped for fluorescence under a 63× objective. Images were captured with a CCD digital camera (AxioCam, Zeiss).
Global DNA methylation analysis
"Methylamp Global DNA methylation quantification kit" (Epigentek, USA) was used to quantify global DNA methylation. 200 ng of genomic DNA extracted from cell samples was immobilized in the strip well specifically treated to have high affinity to DNA for 2 hours at 37°C. The methylated fraction of DNA can be recognized by sequential incubation with 5-methylcytosine antibody for 45 minutes at 37°C, and with secondary antibody for 60 minutes at room temperature. A colorimetric reaction allowed methylated DNA quantification at 450 nM with microplate reader. A methylated DNA was used as positive control. The analysis was repeated twice.
Slot Blot analysis
The DNA-slot blot analysis of 5-Methylcytosine was performed as described  with the following modifications. Purified DNA (100 μg/25 μL) from control, siDNMT1/p14ARF and siDNMT1/p53 IMR90 cells, was denatured at 100°C for 5 min and applied onto Hybond-N membrane (RPN203N, Amersham) using the Hybri-slot Manifold Apparatus (Whatman Biometra, Germany) under vacuum for 3 min. DNA was fixed to the membrane by exposing to UV light (90,000 μjoules/cm2) for 45 seconds using the Hoefer UVC 50 Crossliker (Amersham Biosciences). Samples were then treated with TBST, (0.05% Tween20), 5% w/v no-fat dry milk blocking buffer for 1 hour at RT and incubated with 5-Methylcytosine Monoclonal Antibody (1:500, cloneD33, Epigentek USA) in TBST (0.05% Tween20) 5% w/v no-fat dry milk blocking buffer for 1 hour at RT. The membrane was then washed with TBST (0.05% Tween20), 3 times for 10 minutes each, incubated with HRP conjugated secondary antibody anti-mouse (1:2000) (Abcam, UK) in blocking buffer for 1 hour at RT, washed again with TBST (0.05% Tween20), 3 times for 10 minutes each and once in double distilled water for 5 minutes, then developed by enhanced chemiluminescence detection reagents (Pierce Thermo Scientific) and image acquired with Chemidoc XSR Imaging System (BioRad). Spotted DNA quantity was detected by 0.02% w/v methylene blue in 0.3 M sodium acetate (pH5.2) followed by washing in double distilled water to reduce background noise. The relative 5 MeC Optical density (OD) value was calculated with Quantity One 4.6.7 software relative to DNA amount loaded and normalized to wild type sample.
We are very grateful to Davide F. Corona (University of Palermo) for his valuable comments on the manuscript. This work was partly supported by grant from University of Palermo to ADL.
- Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature 1998,396(6712):643–649. 10.1038/25292View ArticlePubMedGoogle Scholar
- Lingle WL, Barrett SL, Negron VC, D'Assoro AB, Boeneman K, Liu W, Whitehead CM, Reynolds C, Salisbury JL: Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA 2002,99(4):1978–1983. 10.1073/pnas.032479999View ArticlePubMedPubMed CentralGoogle Scholar
- Pihan GA, Doxsey SJ: The mitotic machinery as a source of genetic instability in cancer. Semin Cancer Biol 1999,9(4):289–302. 10.1006/scbi.1999.0131View ArticlePubMedGoogle Scholar
- Fukasawa K: Centrosome amplification, chromosome instability and cancer development. Cancer Lett 2005,230(1):6–19. 10.1016/j.canlet.2004.12.028View ArticlePubMedGoogle Scholar
- Lentini L, Pipitone L, Di Leonardo A: Functional inactivation of pRB results in aneuploid mammalian cells after release from a mitotic block. Neoplasia 2002,4(5):380–387. 10.1038/sj.neo.7900256View ArticlePubMedPubMed CentralGoogle Scholar
- Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, Lowe SW, Cordon-Cardo C: Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 2004,430(7001):797–802. 10.1038/nature02820View ArticlePubMedGoogle Scholar
- Iovino F, Lentini L, Amato A, Di Leonardo A: RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts. Mol Cancer 2006, 5: 38. 10.1186/1476-4598-5-38View ArticlePubMedPubMed CentralGoogle Scholar
- Herrera LA, Prada D, Andonegui MA, Duenas-Gonzalez A: The epigenetic origin of aneuploidy. Curr Genomics 2008,9(1):43–50. 10.2174/138920208783884883View ArticlePubMedPubMed CentralGoogle Scholar
- Costello JF, Plass C: Methylation matters. J Med Genet 2001,38(5):285–303. 10.1136/jmg.38.5.285View ArticlePubMedPubMed CentralGoogle Scholar
- Karpf AR, Matsui S: Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells. Cancer Res 2005,65(19):8635–8639. 10.1158/0008-5472.CAN-05-1961View ArticlePubMedGoogle Scholar
- Luczak MW, Jagodzinski PP: The role of DNA methylation in cancer development. Folia Histochem Cytobiol 2006,44(3):143–154.PubMedGoogle Scholar
- Hervouet E, Lalier L, Debien E, Cheray M, Geairon A, Rogniaux H, Loussouarn D, Martin SA, Vallette FM, Cartron PF: Disruption of Dnmt1/PCNA/UHRF1 interactions promotes tumorigenesis from human and mice glial cells. PLoS One 2010,5(6):e11333. 10.1371/journal.pone.0011333View ArticlePubMedPubMed CentralGoogle Scholar
- Burri N, Shaw P, Bouzourene H, Sordat I, Sordat B, Gillet M, Schorderet D, Bosman FT, Chaubert P: Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. Lab Invest 2001,81(2):217–229. 10.1038/labinvest.3780230View ArticlePubMedGoogle Scholar
- James SR, Link PA, Karpf AR: Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b. Oncogene 2006,25(52):6975–6985. 10.1038/sj.onc.1209678View ArticlePubMedGoogle Scholar
- Chuang LS, Ian HI, Koh TW, Ng HH, Xu G, Li BF: Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. Science 1997,277(5334):1996–2000. 10.1126/science.277.5334.1996View ArticlePubMedGoogle Scholar
- Wang S, El-Deiry WS: p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints. Cancer research 2006,66(14):6982–6989. 10.1158/0008-5472.CAN-06-0511View ArticlePubMedGoogle Scholar
- Easwaran HP, Schermelleh L, Leonhardt H, Cardoso MC: Replication-independent chromatin loading of Dnmt1 during G2 and M phases. EMBO Rep 2004,5(12):1181–1186. 10.1038/sj.embor.7400295View ArticlePubMedPubMed CentralGoogle Scholar
- Bestor TH: The DNA methyltransferases of mammals. Hum Mol Genet 2000,9(16):2395–2402. 10.1093/hmg/9.16.2395View ArticlePubMedGoogle Scholar
- Bird A: DNA methylation patterns and epigenetic memory. Genes Dev 2002,16(1):6–21. 10.1101/gad.947102View ArticlePubMedGoogle Scholar
- Li E: Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet 2002,3(9):662–673. 10.1038/nrg887View ArticlePubMedGoogle Scholar
- Hermann A, Gowher H, Jeltsch A: Biochemistry and biology of mammalian DNA methyltransferases. Cell Mol Life Sci 2004,61(19–20):2571–2587. 10.1007/s00018-004-4201-1View ArticlePubMedGoogle Scholar
- Robertson KD: DNA methylation and human disease. Nat Rev Genet 2005,6(8):597–610.View ArticlePubMedGoogle Scholar
- Shvachko LP: DNA hypomethylation as Achilles' heel of tumorigenesis: a working hypothesis. Cell Biol Int 2009,33(8):904–910. 10.1016/j.cellbi.2009.02.018View ArticlePubMedGoogle Scholar
- Costa FF, Paixao VA, Cavalher FP, Ribeiro KB, Cunha IW, Rinck JA Jr, O'Hare M, Mackay A, Soares FA, Brentani RR, Camargo AA: SATR-1 hypomethylation is a common and early event in breast cancer. Cancer Genet Cytogenet 2006,165(2):135–143. 10.1016/j.cancergencyto.2005.07.023View ArticlePubMedGoogle Scholar
- Watanabe Y, Maekawa M: Methylation of DNA in cancer. Adv Clin Chem 2010, 52: 145–167.View ArticlePubMedGoogle Scholar
- Zeimet AG, Fiegl H, Goebel G, Kopp F, Allasia C, Reimer D, Steppan I, Mueller-Holzner E, Ehrlich M, Marth C: DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer. Gynecol Oncol 2011,121(1):24–31. 10.1016/j.ygyno.2010.12.332View ArticlePubMedPubMed CentralGoogle Scholar
- Stimpson KM, Sullivan BA: Epigenomics of centromere assembly and function. Curr Opin Cell Biol 2010,22(6):772–780. 10.1016/j.ceb.2010.07.002View ArticlePubMedGoogle Scholar
- Gieni RS, Chan GK, Hendzel MJ: Epigenetics regulate centromere formation and kinetochore function. J Cell Biochem 2008,104(6):2027–2039. 10.1002/jcb.21767View ArticlePubMedGoogle Scholar
- de Plater L, Lauge A, Guyader C, Poupon MF, Assayag F, de Cremoux P, Vincent-Salomon A, Stoppa-Lyonnet D, Sigal-Zafrani B, Fontaine JJ, Brough R, Lord CJ, Ashworth A, Cottu P, Decaudin D, Marangoni E: Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. Br J Cancer 2010,103(8):1192–1200. 10.1038/sj.bjc.6605900View ArticlePubMedPubMed CentralGoogle Scholar
- Shukla V, Coumoul X, Lahusen T, Wang RH, Xu X, Vassilopoulos A, Xiao C, Lee MH, Man YG, Ouchi M, Ouchi T, Deng CX: BRCA1 affects global DNA methylation through regulation of DNMT1. Cell Res 2010,20(11):1201–1215. 10.1038/cr.2010.128View ArticlePubMedGoogle Scholar
- De Marzo AM, Marchi VL, Yang ES, Veeraswamy R, Lin X, Nelson WG: Abnormal regulation of DNA methyltransferase expression during colorectal carcinogenesis. Cancer Res 1999,59(16):3855–3860.PubMedGoogle Scholar
- Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998,282(5393):1497–1501.View ArticlePubMedGoogle Scholar
- Frame FM, Rogoff HA, Pickering MT, Cress WD, Kowalik TF: E2F1 induces MRN foci formation and a cell cycle checkpoint response in human fibroblasts. Oncogene 2006,25(23):3258–3266. 10.1038/sj.onc.1209352View ArticlePubMedGoogle Scholar
- Vivo M, Di Costanzo A, Fortugno P, Pollice A, Calabro V, La Mantia G: Downregulation of DeltaNp63alpha in keratinocytes by p14ARF-mediated SUMO-conjugation and degradation. Cell Cycle 2009,8(21):3537–3543. 10.4161/cc.8.21.9935View ArticleGoogle Scholar
- Pereira MA, Wang W, Kramer PM, Tao L: DNA hypomethylation induced by non-genotoxic carcinogens in mouse and rat colon. Cancer Lett 2004,212(2):145–151. 10.1016/j.canlet.2004.03.024View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.